First Ever Automated Mapping Of A Patient’s Right Atrium Completed With Stereotaxis, Inc. System

ST. LOUIS, Nov. 10 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. today announced that the first automated mapping of a patient’s right atrial heart chamber in conjunction with the treatment of a difficult to ablate tachyarrhythmia was successfully completed using the Company’s Niobe(R) Magnetic Navigation System. The mapping procedure was completed by Warren Jackman, M.D., Director of Clinical Electrophysiology, at the University of Oklahoma Health Sciences Center. The automated mapping feature allowed him to move a magnetically navigated catheter to 49 places in the chamber of a beating heart in approximately six minutes, all with a touch of a button on the Niobe system, in order to better define the anatomy of the chamber and more precisely reach the target site to effectively treat the arrhythmia. Atrial tachyarrhythmia is characterized by an abnormal, excessively rapid heartbeat originating in the upper region of the heart.

“Until today, in order to map the timing of activation of a heart chamber, it was necessary to manually advance and rotate a somewhat stiff catheter in an effort to touch multiple points within the chamber,” stated Dr. Jackman. “Certain sites are very difficult to reach manually. The completely automatic mapping of the right chamber that we successfully accomplished today with the Stereotaxis Niobe system, used in conjunction with the Biosense Carto RMT system, allowed our team to quickly find the location for successful ablation in a seventeen-year-old patient who had been referred to us after undergoing an unsuccessful manual ablation procedure in which the correct ablation site could not be located.”

Stereotaxis believes that its Niobe system will be able to improve both the efficiency and efficacy of electrophysiology mapping procedures, while making the time required to perform the procedure more predictable. In addition, the consistent “soft-touch” contact with the heart wall unique to magnetically navigated catheters may reduce the risk of perforation while providing a more accurate map of the patient’s anatomy than can be achieved via manual navigation. The electrophysiology catheters used for mapping in the procedure are commercially available in the United States.

“Our system has now been utilized to automate the mapping of both the left and right atria,” commented Bevil Hogg, Stereotaxis’ President and CEO. “The successful completion of these procedures reinforces our belief that bringing automated remote navigation and control to certain long and complex interventional procedures will improve physician dexterity, and increase procedural efficiency and efficacy, while significantly reducing x-ray exposure.”

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire. Core components of the Stereotaxis System have received regulatory clearance in the U.S. and Europe.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contacts: Stereotaxis, Inc. Noonan Russo 314-615-6957 212-845-4269 Jim Stolze, Chief Financial Officer Brian Ritchie (investors) jstolze@stereotaxis.combrian.ritchie@eurorscg.com

Stereotaxis, Inc.

CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis, Inc.,+1-314-615-6957, jstolze@stereotaxis.com; or Brian Ritchie - investors ofNoonan Russo for Stereotaxis, Inc., +1-212-845-4269,brian.ritchie@eurorscg.com

MORE ON THIS TOPIC